Investor Presentaiton

• " • Updates on Innovation NCE: Saroglitazar Magnesium zydus Dedicated To Life Global pivotal Phase II(b)/III CT viz. EPICS-III™ to evaluate the efficacy and safety of the molecule in patients with PBC is currently going on for the US market. Patient enrolment ongoing for EVIDENCES-X, another global pivotal Phase II(b) CT to evaluate the efficacy and safety of the molecule in subjects with NASH and Fibrosis indications. NCE: Desidustat • Received marketing authorization from DCGI for the molecule for the treatment of anemia in patients with CKD. The molecule has been launched in India in March, 2022 under the brand name Oxemia TM. It is our 2nd NCE developed exclusively from lab to market. On the global development front, Phase III clinical trials underway in China for management of anemia in CKD patients. NCE: ZY19489 (Anti-malarial) The molecule is fast acting and effective against both P. falciparum and P. vivax strains of malarial parasites. It is being developed to provide an effective alternative to the current front-line antimalarial drugs, as artemisinin-based combination therapies (ACTS) are under immediate threat of resistance. Phase I study in healthy volunteers demonstrated long-half life and good safety profile. CT = Clinical Trial; NASH = Non-Alcoholic Steatohepatitis, PBC = Primary Biliary Cholangitis, DCGI = Drug Controller General of India, CKD = Chronic Kidney Disease 10

View entire presentation